| INTRODUCTION
Radiation Oncology is a highly multidisciplinary medical specialty, drawing significantly from three scientific disciplines -medicine, physics, and biology. As a result, discussion of or changes in practice within radiation oncology involves input from all three disciplines. For this reason, significant effort has been expended recently to foster collaborative multidisciplinary research in radiation oncology, with substantial demonstrated benefit. 1, 2 In light of these results, we endeavor here to adopt this "team-science" approach to the traditional debates featured in this journal. This article represents the third in a series of special debates entitled "Three Discipline Collaborative Radiation Therapy (3DCRT)" in which each debate team will include a radiation oncologist, medical physicist, and radiobiologist. We hope that this format will not only be engaging for the readership but will also foster further collaboration in the science and clinical practice of radiation oncology. The advent of Intensity Modulated Radiation Therapy (IMRT) has significantly improved our ability to shape the dose distribution around tumors to spare adjacent normal tissue structures. The treatment of tumors in the head and neck has benefited substantially from this capability since there are typically many adjacent normal tissue structures and both tumors and organs at risk (OARs) tend to be complex in shape. However, creating more conformal treatment plans requires more accurate knowledge of the location and shape of patient anatomy. Anatomical changes throughout the course of treatment can result in significant changes in the delivered dose distribution, thus prompting the creation of new plans during the course of treatment to adapt to these anatomical changes. However, this necessitates a significant increase in workload for radiotherapy staff, increases the cost of care, and provides no guarantee that the anatomy will be the same when the adapted plan is ready to be delivered. Given the potential theoretical improvement in the delivered dose distribution, one may question whether all head and neck cancer patients should receive adaptive replanning. This is the subject of this month's three discipline collaborative radiation therapy debate.
Arguing for the proposition will be Drs. Emilie Soisson, Patrizia 
radiotherapy can be made more effective using manipulations of the radiation delivery schedule. He discovered low-dose hyper-radiosensitivity, a major factor influencing the extent and type of signaling and DNA repair following x-ray exposure and therefore determining overall tumor effect and tissue toxicity. IMRT, irradiation of the mucosa cannot be completely avoided due to disease extent, and weight loss must be considered over the course of radiation therapy. In addition, there can be shrinkage of the gross disease or changes of shape or density of the OARs, which also may lead to volume reduction and increased normal tissue doses.
Ultimately, the goal of adaptive replanning is to periodically change the treatment plan so that the delivered dose will more closely resemble the intended planned dose when treatment induced anatomical changes occur. In the case of head and neck cancers, the main advantage is that the normal tissue tolerances can be respected as the tissue volume decreases by accounting for these changes in the treatment plan via incorporation of new imaging data. With the widespread adoption of daily volumetric imaging, these adjustments could also happen as often as daily, making a "plan of the day" possible. In addition, significant technological innovation on the part of the treatment planning system vendors has removed some of the technical hurdles that have made true daily adaptive therapy challenging to implement. Unfortunately, the vendor-supplied workflows, usually involving automated deformable image registration and dose accumulation, have failed to become the standard of care due to the overhead associated with putting out a new plan, and performing the necessary validation and quality assurance.
While, in theory, delivery accuracy only improves with increased plan frequency, there is limited clinical evidence that daily plan adaptation actually improves dose delivery in a clinically meaningful way for the majority of patients. A prospective multi-institutional trial by Schwartz et al. 3 looking at ART for oropharyngeal squamous cell carcinoma showed that the majority of the dosimetric benefits from adaptive planning can actually be achieved with just one or two midtreatment replans.
In fact, the clinical reality at this point is that most centers are using their adaptive planning workflows to perform only one, or a few, adapted plans. Generally, the plan is unanticipated, and a typical workflow follows: A patient is under treatment and at some fraction something or somebody will trigger the need for a new plan. Examples of these triggers vary widely and could be something from a poorly fitting mask, to a physician noticing differences in anatomy upon pretreatment image review, to a more quantitative flag from a more sophisticated "in vivo" dosimetry system (i.e., EPID). At this point, in most places, the patient would have to then be scheduled for a repeat simulation with the intent to create a new plan in an accelerated time frame (to avoid treating too many fractions with a potentially invalid plan). In many centers, it means that this plan must take priority over other plans, disrupting the clinical workflow, and altering scheduling or staffing needs. Many steps in the planning and QA may be rushed to allow for the short turnaround time, potentially compromising quality and safety.
The proposition would remove this workflow bottleneck by making an a priori assumption that each head and neck patient will need at least one replan. Creation of an adapted plan at a minimum of one point in a patient's treatment would be easily within the realm of possibility in most places. Automated tools could be used to create the plan, the plan could even be screened using an automated system for dosimetric variation, and then, once flagged, the clinical staff would review this plan for clinical meaningful deviation. After review of this scheduled replan, an informed decision could be made by the clinician to either proceed with the current plan or implement the adapted plan.
Data gathered from this mandated replanning may also make it possible to come up with institution and patient specific predictive factors for anatomical change that will lead to significant dosimetric deviations during treatment. In the future, these adaptive plans could potentially be scheduled at particular time-points based on the patient's unique risk of requiring one. In addition, scheduled replanning will allow for the incorporation of information regarding treatment response obtained from other image modalities.
It is well known that tumor oxygenation is an important factor in tumor cell kill. The distribution of oxygenated cells within a tumor is nonuniform over time due to changes in tumor vasculature and concomitant hypoxia. 18F-FDG PET is a widely used tool for mapping tumors based on metabolic activity, hypoxia, and cell proliferation, and has been used for adaptation during radiation therapy. 4 Recent computer-based tumor response models suggest that tumor hypoxia based adaptation would be an effective way to reassess treatment dose. 5 In addition, it has been suggested that a weekly reassessment would be as powerful as daily reassessment where the former could be less cumbersome operationally. While the use of 18F-FDG PET might be challenging due to the reactivity in areas of radiation-induced inflammation, this shortcoming could be avoided by using other tracers such as 18F-FMISO that are hypoxia specific. 6 Therefore, using 18F-FDG/ 18F-FMISO PET imaging for assessing tumor metabolism, and using that information for IMRT would be an effective way to improve patients' quality of life as well as reduce normal tissue toxicity. Routine adaptive planning would provide a convenient time point for incorporation of new biological information in the patient's therapy.
In Routine ART for head and neck cancer patients is just not doable. There is an unmet need for robust and efficient tools for existing equipment which are available and able to be safely used in the broader community for patient care. Investigators have retrospectively demonstrated a correlation of changes on daily cone-beam CT (CBCT) to xerostomia using a cumbersome process. Even with validated atlas-based auto-segmentation software, review and manual correction of target volumes and normal organs contours is still needed. 9 The tools for ART are not yet robust, timely, and widely available. The arguments presented by our opposition clearly demonstrate the impracticality of the notion: while scheduling adaptive planning is a great idea, they emphasize the burden of "overhead associated with putting out a new plan and performing the necessary validation and quality assurance". These activities are cumbersome and wasteful, if an adaptive plan is not used, without a clear benefit to individual patients. Our colleagues cite an important, small pilot study (Schwartz et al.) that showed minor dosimetric benefits for midtreatment replanning but did not show clinical benefit nor was there scientific justification for the timing of replanning. The ideal timing remains under study including new data emerging from daily ontreatment MRI imaging.
The biology of the target is critical: the uncertainty of accurately locating the volume of residual viable tumor at the site of replanning is still unanswered. The specificity and sensitivity of 18F-FDG/18F-FMISO PET remains under study.
Indeed, we agree it would be ideal to avoid the current unexpected decisions to replan, however as a community we lack the needed capabilities in routine practice to automate the process. 
